| United Kingdom|
| Gordon Wishart|
| Addenbrooke’s Hospital, Cambridge BreastHealth UK|
Treatment of breast cancer
University of Edinburgh
Gordon Wishart Wikipedia
Professor Gordon C Wishart MB ChB MA(Cantab.) MD FRCS FRCS (Eng.) FRCS (Gen.) is a consultant breast & endocrine surgeon at Addenbrooke's Hospital, Cambridge. He is distinguished for his pioneering work in the treatment of breast cancer, where he has introduced innovative, and sometimes controversial, techniques which have subsequently seen wide acceptance and adoption.
Gordon Cranston Wishart was born in Edinburgh, Scotland, on 3 September 1960.
He studied at Edinburgh University Medical School, where he obtained his MB ChB (Bachelor of Medicine, Bachelor of Surgery) degree in July 1983.
He subsequently obtained his MD from Edinburgh University in June 1992 with a thesis entitled Aspects of multidrug resistance in breast cancer.
Gordon Wishart is notable for his prolific clinical research output, alongside his work as a practising breast and endocrine surgeon. He has published widely and has received numerous prizes for his papers, including Best paper: British Association of Day Surgery 2002; British Journal of Surgery Prize for best paper at British Association of Endocrine Surgeons, September 2006; and British Journal of Surgery Prize for best paper at British Association of Endocrine Surgeons, September 2007.
As of October 2009 he is principal investigator on the following studies:Reasons for improved survival in screen-detected breast cancer
Development of a UK version of Adjuvantonline.
Infrared Imaging for breast cancer diagnosis
BT blood test for breast cancer detection
In addition he is co-investigator, surgical coordinator or clinical surgical coordinator on an additional 15 research studies.
His research has been published in The Lancet, the British Journal of Cancer, the British Medical Journal, the Journal of Clinical Oncology and the British Journal of Surgery, among others.In 1990, Gordon Wishart identified that P-glycoprotein, a trans-membrane export pump involved in multidrug resistance, was present in breast cancer.
In 1998, he introduced early patient discharge, with wound drains still in situ, following breast cancer surgery. Although controversial at the time this technique has since been widely adopted.
Wishart pioneered minimally invasive parathyroid surgery as a daycase procedure in the UK, together with the use of intra-operative parathyroid hormone (PTH) measurement for parathyroid surgery.
In 2007, Wishart piloted gold seed insertion following breast conserving surgery for breast cancer to facilitate targeted radiotherapy.
In 2009, he pioneered pre-operative axillary lymph node staging in breast cancer treatment.
Gordon Wishart currently holds the following posts:Medical Director, BreastHealth UK]
Visiting Professor of Cancer Surgery, Anglia Ruskin University
Associate Lecturer, Faculty of Clinical Medicine, University of Cambridge
He also acts as a referee for the British Journal of Surgery, the European Journal of Surgical Oncology, and Nuclear Medicine Communications.